Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Sinobioway Raises Offer for Vaccine Maker Sinovac to $459 Million

publication date: Jun 30, 2017
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Shandong Sinobioway Biomedicine topped management's $402 million bid to privatize China vaccine maker Sinovac with a $459 million offer of its own. Sinobioway also criticized Sinovac's board for its lack of transparency. Eighteen months ago, when the Sinovac privatization saga started, Sinobioway offered $7 per share for Sinovac, improving on management's earlier $6.18 offer. Sinovac's board responded by instituting a poison pill and going silent on the proceedings. This week, Sinovac announced it had accepted management's newly raised $7 bid -- a bid that had never been publicly announced. Now, Sinobioway is offering $8 per share or $459 million. More details....

Stock Symbols: (SZE: 002581) (NSDQ: SVA)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login